Intense competition from Viking Therapeutics and Amgen, may result in a new best in class GLP-1 drug, further threatening Novo's moat. The Company's valuation remains high at 33.2x forward ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA). The ...

SAN AN­TO­NIO — Well be­hind No­vo Nordisk and Eli Lil­ly in the obe­si­ty race, As­traZeneca came to this year’s Obe­si­ty­Week with three as­sets in hand … ...

For years, drug de­vel­op­ers work­ing to treat an ad­vanced form of fat­ty liv­er dis­ease known as MASH were chas­ing wide-open ter­rain. There were no prod­ucts … ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) causes almost as much weight loss as ...

Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery technology to advance a long-acting GLP-1 drug as well as develop products in ...